Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from The United Laboratories International Holdings ( (HK:3933) ) is now available.
The United Laboratories International Holdings has reported positive Phase II clinical results for UBT251 Injection, a long-acting triple-target GLP-1/GIP/GCG receptor agonist developed by its wholly owned unit United Biotechnology, in Chinese patients with overweight or obesity. In the 24-week randomized, double-blind, placebo-controlled trial involving 205 patients, UBT251 achieved up to a 19.7% reduction in body weight versus 2.0% for placebo, alongside significant improvements in waist circumference, blood glucose, blood pressure and blood lipids, with a safety profile comparable to other drugs in the class and no withdrawals due to adverse events.
The company said the data support advancing UBT251 into Phase III trials in Chinese overweight and obese patients, reinforcing its position in the fast-growing metabolic disease treatment market. UBT251, for which the company already holds clinical approvals in China and the U.S. across multiple indications, gained further validation in March 2025 when United Biotechnology and the group entered an exclusive license agreement with Novo Nordisk, underlining the strategic and commercial potential of this triple agonist platform.
The robust efficacy and tolerability outcomes could strengthen the company’s competitive edge as one of the first in China, and second globally, to bring a chemically synthesized long-acting triple agonist into advanced clinical development. Investors and industry stakeholders will be watching the upcoming Phase III program closely, as successful late-stage results could accelerate commercialization prospects and deepen partnerships in the global obesity and metabolic disease market.
The most recent analyst rating on (HK:3933) stock is a Hold with a HK$13.00 price target. To see the full list of analyst forecasts on The United Laboratories International Holdings stock, see the HK:3933 Stock Forecast page.
More about The United Laboratories International Holdings
The United Laboratories International Holdings is a pharmaceutical group based in China, operating through subsidiaries such as The United Bio-Technology (Hengqing). The company focuses on innovative drug development targeting metabolic and chronic diseases, including type 2 diabetes, obesity, chronic kidney disease and metabolic dysfunction-associated steatohepatitis, and is among the early movers in China in GLP-1-based multi-agonist therapies.
Average Trading Volume: 9,017,263
Technical Sentiment Signal: Buy
Current Market Cap: HK$24.84B
For an in-depth examination of 3933 stock, go to TipRanks’ Overview page.